**CONTENTS**

|  |  |  |
| --- | --- | --- |
|  |  | **Page No.** |
| 1. | **INTRODUCTION** |  |
|  | 1. 1. What is Cancer? |  |
|  | 1. 2. Traits of cancer cells |  |
|  | 1. 3. Oncogenes, Tumour Suppressor Genes, DNA repair Genes and their roles in carcinogenesis |  |
|  | 1. 4. Types of cancer |  |
|  | 1. 5. Stages of cancer |  |
|  | 1. 6. Common risk factors for cancer |  |
|  | 1. 7. Symptoms of cancer |  |
|  | 1. 8. Diagnosis of cancer |  |
|  | 1. 9. General treatment options for cancer patients |  |
|  | 1. 10. BC |  |
|  | 1. 11. Prevention |  |
|  | 1. 12. Therapies for BC |  |
|  | 1. 13. Epidemiology of BC |  |
|  |  |  |
| **2.** | **REVIEW OF LITERATURE** |  |
|  | 2. 1. RNA interference (RNAi) |  |
|  | 2. 2. RNAi pathways |  |
|  | 2. 3. Role of miRNA in cancer |  |
|  | 2. 4. Oncogenic role of miRNAs in cancer |  |
|  | 2. 5. Tumour suppressor role of miRNAs |  |
|  | 2. 6. Recent developments in miRNA therapies for human disease prevention and treatment |  |
|  | 2. 7. MiRNA-based treatment approach |  |
|  | 2. 8. Inhibition of miRNAs |  |
|  | 2. 9. Inhibition of miRNAs by antisense oligonucleotides (AMOs) and anti-miRNA oligonucleotides (AmMOs) |  |
|  | 2. 10. MicroRNA replacement |  |
|  | 2. 11. Viral vector-based miRNA replacement |  |
|  | 2. 12. Non-viral miRNA replacement |  |
|  | 2. 13. MicroRNA-375 |  |
|  | 2. 14. MicroRNA-375 interferes in tumour suppressor activity in various cancer |  |
|  | 2. 15. Hepatocellular Carcinoma (HCC) |  |
|  | 2. 16. Gastrointestinal tract cancers |  |
|  | 2. 17. Esophagus Cancer |  |
|  | 2. 18. Head and Neck Cancer |  |
|  | 2. 19. Involvement of microRNA-375 in other cancers |  |
|  | 2. 20. HOX Genes in Growth & pathological condition |  |
|  | 2. 21. HoxA5 functions in the development and disease |  |
|  | 2. 22. Regulations mechanism of miRNAs in HOXA5 |  |
|  | 2. 23. Nucleolin |  |
|  | 2. 24. Nucleolin in cancer |  |
|  |  |  |
| **3.** | **AIM & OBJECTIVES** |  |
|  | 3. 1. Aim |  |
|  | 3. 2. Objectives |  |
|  | MATERIALS & METHODS |  |
|  | 4. 1. Materials & Methods |  |
|  | 4. 2. Transfection of miRNA Mimics, Inhibitor, siRNA, and Negative Controls |  |
|  | 4. 3. Bioinformatics Analysis |  |
|  | 4. 4. Cellular Morphological Assay |  |
|  | 4. 5. Cell viability test |  |
|  | 4. 6. Ethidium Bromide /Acridine Orange (EtBr/AO) Dual Staining |  |
|  | 4. 7. Reactive Oxygen Species (ROS) Formation Assessment |  |
|  | 4. 8. Mitochondrial membrane potential Assay |  |
|  | 4. 9. Scratch analysis |  |
|  | 4. 10. Invasion & migration assay |  |
|  | 4. 11. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) |  |
|  | 4. 12. Chemosensitivity assay |  |
|  | 4. 13. Western Blotting |  |
|  | 4. 14. Statistical Analysis |  |
|  |  |  |
| **5.** | **RESULTS** |  |
|  | 5. 1. MicroRNA-375 & HOXA5 Clinical Significance in Breast Cancer Patients |  |
|  | 5. 2. MicroRNA-375 Inhibition Reduced Breast Cancer Cell Viability |  |
|  | 5. 3. Silencing of microRNA-375 Induced Apoptosis and ROS Generation in BC Cells |  |
|  | 5. 4. MicroRNA-375 Inhibition Reduces Migration & Invasion |  |
|  | 5. 5. Silencing of microRNA-375 Reduces PI3K/Akt/mTOR & Regulates Apoptosis Involved Gene Expression |  |
|  | 5. 6. Nucleolin Regulates microRNA-375/HOXA5 Axis |  |
|  | 5. 7. Inhibition of Nucleolin Deregulates Apoptosis Gene Expression |  |
|  | 5. 8. MicroRNA-375 knockdown promotes chemosensitivity in BC cells to doxorubicin. |  |
|  |  |  |
| **6.** | **DISCUSSION** |  |
|  | 6. 1. Overall discussion |  |
|  | 6. 2. Summary |  |
|  |  |  |
| **7.** | **CONCLUSION** |  |
|  |  |  |
| **8.** | **REFERENCES** |  |
|  |  |  |
|  | **GLOSSARY WORDS** |  |

**LIST OF FIGURES**

|  |  |  |
| --- | --- | --- |
| **Figure**  **No.** | **Title** | **Page No.** |
| 1. 1. | Representation of cancer initiation and progression |  |
| 1. 2. | Cancer hallmarks |  |
| 1. 3. | Cancer incidence and mortality in 2020 |  |
| 1. 4. | Pie chart of cancer incidence and mortality |  |
| 1. 5. | Age standardised rate of incidence and mortality |  |
| 1. 6. | Age standardised rate of incidence and mortality in females |  |
| 1. 7. | Breast cancer incidence and mortality worldwide. |  |
| 1. 8. | Predicted cancer outcome in various economies |  |
| 2. 1. | Mode of action of Small interfering RNAs |  |
| 2. 2. | Oncogenic role of microRNAs in cancer |  |
| 2. 3. | Different types of microRNA therapeutics |  |
| 2. 4. | MicroRNA-375 tumour suppressive role in cancer. |  |
| 2. 5. | Evolutionary conservation of HOXA5 genes |  |
| 2. 6. | Overview of HOX involvement in different tumours in humans. |  |
| 2. 7. | HOX gene regulation in cancer modulated by genetic and epigenetic mechanism |  |
| 2. 8. | The homology tree illustrates the homological relationship of the HOXA5 protein with other HOX family proteins. |  |
| 2. 9. | MicroRNAs and HOXA5 in cancer |  |
| 2. 10. | Role of nucleolin in tumourigenesis |  |
| 5. 1. | MicroRNA-375 and HOXA5 correlated expression in BC primary tumours. |  |
| 5. 2. | Effect of miR-M, miR-I and miR-NC on BC cells |  |
| 5. 3. | Inhibition of microRNA-375 enhanced cell death in breast cancer cells |  |
| 5. 4. | MicroRNA-375 knockdown decreased cell migration in breast cancer cells in vitro. |  |
| 5. 5. | MicroRNA-375 regulates PI3K/AKT signalling pathway and apoptotic, anti-apoptotic proteins in breast cancer cell lines. |  |
| 5. 6. | Nucleolin expression correlation in BC cells. |  |
| 5. 7. | Nucleolin regulates apoptotic and anti-apoptotic mRNA expression in breast cancer cells. |  |
| 5. 8. | MiR-I improved doxorubicin sensitivity in BC cells |  |

**LIST OF TABLES**

|  |  |  |
| --- | --- | --- |
| **Table No.** | **Title** | **Page No** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |